




STATE MEDICAID P&T COMMITTEE MEETING
 THURSDAY, November 21, 2013
 7:00 a.m. to 8:30 a.m.
 Cannon Health Building
 Room 114



MINUTES

Committee Members Present:

Kort Delost, R.Ph.
 Julia Ozbolt, M.D.
 Beth Johnson, R.Ph.

Jameson Rice, Pharm.D.
 Roger Martenau, M.D.
 Elizabeth Young, Pharm.D.

Committee Members Excused:

Ellie Brownstein, M.D.
 Lisa Hunt, R.Ph.

Bernadette Kiraly, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Timothy Morley R.Ph.
 Trevor Smith, C.Ph.T.

Robyn Seely, Pharm.D.
 Richard Sorenson R.N.

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Gary Oderda, Pharm.D, MPH

Other Individuals Present:

Scott Larson, BMS
 Paul Bonham, NovoNordisk

Mark German, Novartis

Meeting conducted by: Kort Delost

1. **Review and Approval of October Minutes:** Beth Young moved to approve the minutes. Beth Johnson seconded the motion. The vote was unanimous and the motion carried. Corrected minutes from September's meeting were also presented.
2. **Housekeeping:** Robyn Seely is filling in for Lisa Hunt, who is absent, in preparation of the meeting.
3. **Drug Utilization Review (DUR) Board update:** Robyn Seely stated that the DUR Board met the previous Thursday to discuss Tudorza and also several anti-diabetic classes were discussed resulting in the simplification and consistency in criteria required for them. There will be no DUR Board meeting in December.

4. **Phosphate Biding Agents Review:** Melissa Archer presented a review of Phosphate Binging. Peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.
5. **Other States Report:** Robyn Seely presented data from other states Preferred Drug Lists and coverage status.
6. **No Public comment**
7. **Committee discussion**
 - a. Committee members questioned why other states have brand name products listed as preferred in place of the generic. Robyn Seely said that in many cases the end cost for brand name medications end up lower after rebates than the generics.
 - b. Melissa Archer said that in this drug class, it is common to see the brand name agents have more utilization than generics because of issues with calcium levels in patients.
 - c. Jameson Rice mentioned the different dose formulations in the drugs.
 - d. Kort Delost said that with the exception of patients with hypercalcemia, the agents seem equally safe and effective. Other committee members were in agreement.
 - e. Jameson Rice made a motion saying that with the exception of patients with hypercalcemia, the agents are equally safe and effective. Beth Young seconds the motion. All in favor.
 - f. It was decided to allow the state to determine coverage of the class while looking at utilization and cost.
 - g. A question was made about if a motion needs to be made about including a non calcium containing product on the list.
 - h. Beth Johnson made a motion that at least one of the included agents be a non calcium containing agent.
 - i. Discussion about including more than one drug class per meeting so the time is used effectively. Melissa Archer said that it is hard to determine the amount of time that will be used especially with the possibility of public comment.
 - j. The committee asked that the January scheduled meeting on Pediculosides include another topic.

8. Next meeting is scheduled for December 19, 2013. Topical Immune Modulators and

topical/local anesthetic agents will be discussed.

9. Roger Martenau made a motion to close the meeting. Beth Johnson seconded the motion. The vote was unanimous. The motion carried and the meeting was adjourned.

Minutes prepared by Trevor Smith

Recording available upon request, send email to medicaidpharmacy@utah.gov